Peritoneal dialysis in patients with end-stage renal disease, chronic liver disease and ascites: A prospective observational study.

IF 0.5 Q4 UROLOGY & NEPHROLOGY
Abdullah Al-Hwiesh, Ibrahiem Saeed Abdul-Rahman, Mohammed Ahmed Nasreldin, Moaz Abdulgalil, Khadija M Alshehabi, Nadia Al-Audah, Abdullah D Alotibi, Suzan Aloudah
{"title":"Peritoneal dialysis in patients with end-stage renal disease, chronic liver disease and ascites: A prospective observational study.","authors":"Abdullah Al-Hwiesh, Ibrahiem Saeed Abdul-Rahman, Mohammed Ahmed Nasreldin, Moaz Abdulgalil, Khadija M Alshehabi, Nadia Al-Audah, Abdullah D Alotibi, Suzan Aloudah","doi":"10.4103/sjkdt.sjkdt_205_25","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Patients with chronic liver disease (CLD) complicated by ascites may develop end-stage renal disease (ESRD), making selection of renal replacement therapy challenging. This study described the feasibility and clinical outcomes of peritoneal dialysis (PD) in selected patients with ESRD, CLD, and ascites.</p><p><strong>Patients and methods: </strong>This prospective observational study included 51 selected patients with ESRD, CLD, and ascites and 55 patients with ESRD without CLD who underwent PD at a tertiary university hospital in Saudi Arabia. All underwent percutaneous insertion of a three-cuff PD catheter and received automated peritoneal dialysis (APD). Clinical outcomes recorded during observed follow-up are presented descriptively.</p><p><strong>Results: </strong>Percutaneous catheter insertion was successful in all patients without bowel perforation, catheter migration, or major hemorrhage. Thirteen peritonitis episodes were recorded in the CLD group and 12 in the non-CLD group. The overall peritonitis rate was 0.10 episodes per patient-year; group-specific rates were 0.11 and 0.09 episodes per patient-year, respectively. None required catheter removal. A transient serum albumin decline of at least 0.5 g/dL was recorded in 5 and 4 patients, respectively. Early dialysate leakage occurred in 7/51 and 3/55 patients and was managed by temporary reduction of fill volume. During observed follow-up, 12/51 patients with CLD and 9/55 patients without CLD died.</p><p><strong>Conclusions: </strong>Peritoneal dialysis was feasible in this selected cohort of patients with ESRD, chronic liver disease, and ascites. The observed adequacy values, complication counts, and crude mortality are reported descriptively. The findings should not be interpreted as establishing safety, effectiveness, equivalence, or superiority.</p>","PeriodicalId":21356,"journal":{"name":"Saudi Journal of Kidney Diseases and Transplantation","volume":"37 3","pages":"210-216"},"PeriodicalIF":0.5000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Saudi Journal of Kidney Diseases and Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/sjkdt.sjkdt_205_25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/28 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Patients with chronic liver disease (CLD) complicated by ascites may develop end-stage renal disease (ESRD), making selection of renal replacement therapy challenging. This study described the feasibility and clinical outcomes of peritoneal dialysis (PD) in selected patients with ESRD, CLD, and ascites.

Patients and methods: This prospective observational study included 51 selected patients with ESRD, CLD, and ascites and 55 patients with ESRD without CLD who underwent PD at a tertiary university hospital in Saudi Arabia. All underwent percutaneous insertion of a three-cuff PD catheter and received automated peritoneal dialysis (APD). Clinical outcomes recorded during observed follow-up are presented descriptively.

Results: Percutaneous catheter insertion was successful in all patients without bowel perforation, catheter migration, or major hemorrhage. Thirteen peritonitis episodes were recorded in the CLD group and 12 in the non-CLD group. The overall peritonitis rate was 0.10 episodes per patient-year; group-specific rates were 0.11 and 0.09 episodes per patient-year, respectively. None required catheter removal. A transient serum albumin decline of at least 0.5 g/dL was recorded in 5 and 4 patients, respectively. Early dialysate leakage occurred in 7/51 and 3/55 patients and was managed by temporary reduction of fill volume. During observed follow-up, 12/51 patients with CLD and 9/55 patients without CLD died.

Conclusions: Peritoneal dialysis was feasible in this selected cohort of patients with ESRD, chronic liver disease, and ascites. The observed adequacy values, complication counts, and crude mortality are reported descriptively. The findings should not be interpreted as establishing safety, effectiveness, equivalence, or superiority.

腹膜透析治疗终末期肾病、慢性肝病和腹水患者:一项前瞻性观察研究
目的:慢性肝病(CLD)合并腹水的患者可能发展为终末期肾脏疾病(ESRD),这使得肾脏替代治疗的选择具有挑战性。本研究描述了腹膜透析(PD)治疗ESRD、CLD和腹水患者的可行性和临床结果。患者和方法:这项前瞻性观察性研究包括51例ESRD、CLD和腹水患者和55例ESRD无CLD患者,这些患者在沙特阿拉伯的一家三级大学医院接受了PD治疗。所有患者均经皮插入三套PD导管并接受自动腹膜透析(APD)。在观察随访期间记录的临床结果是描述性的。结果:所有患者经皮置管均成功,无肠穿孔、导管移位、大出血。CLD组有13例腹膜炎发作,非CLD组有12例。总腹膜炎发生率为每患者年0.10次;组特异性发生率分别为每患者年0.11次和0.09次。无需要拔除导管。5例和4例患者分别记录了至少0.5 g/dL的短暂血清白蛋白下降。早期透析液渗漏在7/51和3/55患者中发生,并通过暂时减少填充量来处理。随访期间,12/51的CLD患者和9/55的无CLD患者死亡。结论:腹膜透析在ESRD、慢性肝病和腹水患者中是可行的。描述性地报告观察到的充分性值、并发症计数和粗死亡率。研究结果不应被解释为确定安全性、有效性、等效性或优越性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.00
自引率
0.00%
发文量
49
审稿时长
53 weeks
期刊介绍: Saudi Journal of Kidney Diseases and Transplantation (SJKDT, ISSN 1319-2442) is the official publication of the Saudi Center for Organ Transplantation, Riyadh, Saudi Arabia. It is published six times a year. SJKDT publishes peer-reviewed original research work and review papers related to kidney diseases, urinary tract, renal replacement therapies, and transplantation. The journal publishes original papers and reviews on cell therapy and islet transplantation, clinical transplantation, experimental transplantation, immunobiology and genomics and xenotransplantation related to the kidney. The journal also publishes short communications, case studies, letters to the editors, an annotated bibliography and a column on news and views.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书